New HIV drug candidate GS-1219 tested in tiny early trial

NCT ID NCT07115368

Terminated Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GS-1219 (an experimental antiretroviral drug)
What this could lead to: If successful, GS-1219 could become a new option for controlling HIV-1, adding to the arsenal of antiretroviral therapies.
What could go wrong: This was a very early (Phase 1), tiny (4 participants) study that was terminated, so we have very limited data. The drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

AXCES Research Group

El Paso, Texas, 79902, United States
AXCES Research Group

Salt Lake City, Utah, 84102, United States
BLISS Health Inc

Orlando, Florida, 32803, United States
Be Well Medical Center

Berkley, Michigan, 48072, United States
Central Texas Clinical Research

Austin, Texas, 78705, United States
Midland Florida Clinical Research Center

DeLand, Florida, 32720, United States
Midway Immunology and Research Center

Ft. Pierce, Florida, 34982, United States
Mills Clinical Research

Los Angeles, California, 90069, United States
North Texas Infectious Diseases Consultants

Dallas, Texas, 75246, United States
Orlando Immunology Center

Orlando, Florida, 32803, United States
Prism Health North Texas

Dallas, Texas, 75208, United States
Quest Clinical Research

San Francisco, California, 94115, United States
Ruane Clinical Research Group

Los Angeles, California, 90036, United States
Triple O Research Institute

West Palm Beach, Florida, 33407, United States
Washington Health Institute

Washington D.C., District of Columbia, 20017, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.